{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:35:32Z","timestamp":1792899332015,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive fungal infections mainly affect patients undergoing transplantation, surgery, neoplastic disease, immunocompromised subjects and premature infants, and cause over 1.5 million deaths every year. The most common fungi isolated in invasive diseases are <jats:italic>Candida <\/jats:italic>spp<jats:italic>., Cryptococcus <\/jats:italic>spp<jats:italic>., <\/jats:italic>and<jats:italic> Aspergillus <\/jats:italic>spp. and even if four classes of antifungals are available (Azoles, Echinocandins, Polyenes and Pyrimidine analogues), the side effects of drugs and fungal acquired and innate resistance represent the major hurdles to be overcome. Monoclonal antibodies are powerful tools currently used as diagnostic and therapeutic agents in different clinical contexts but not yet developed for the treatment of invasive fungal infections. In this paper we report the development of the first humanized monoclonal antibody specific for \u03b2-1,3 glucans, a vital component of several pathogenic fungi. H5K1 has been tested on <jats:italic>C<\/jats:italic>. <jats:italic>auris,<\/jats:italic> one of the most urgent threats and resulted efficient both alone and in combination with Caspofungin and Amphotericin B showing an enhancement effect. Our results support further preclinical and clinical developments for the use of H5K1 in the treatment of patients in need.<\/jats:p>","DOI":"10.1038\/s41598-021-98659-5","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:30:41Z","timestamp":1632997841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A new humanized antibody is effective against pathogenic fungi in vitro"],"prefix":"10.1038","volume":"11","author":[{"given":"Tomas","family":"Di Mambro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Vanzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Bruscolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Perez-Gaviro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Roscilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fraternale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta Fiorella","family":"Schiavano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"98659_CR1","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","volume":"17","author":"DS Perlin","year":"2017","unstructured":"Perlin, D. S., Rautemaa-Richardson, R. & Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 17, e383\u2013e392 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"98659_CR2","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S1473-3099(17)30442-5","volume":"17","author":"D Armstrong-James","year":"2017","unstructured":"Armstrong-James, D. et al. Immunotherapeutic approaches to treatment of fungal diseases.  Lancet Infect. Dis. 17, e393\u2013e402 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"98659_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/jof3010002","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin, F., Gago, S., Oladele, R. O. & Denning, D. W. Global and multi-national prevalence of fungal diseases-estimate precision. J. Fungi (Basel) 3, 2 (2017).","journal-title":"J. Fungi (Basel)"},{"key":"98659_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/cid\/cis021","volume":"54","author":"DR Andes","year":"2012","unstructured":"Andes, D. R. et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54, 1110\u20131122 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"98659_CR5","doi-asserted-by":"publisher","first-page":"e43582","DOI":"10.1371\/journal.pone.0043582","volume":"7","author":"EW Bratton","year":"2012","unstructured":"Bratton, E. W. et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative\/non-transplant. PLoS\u00a0One 7, e43582 (2012).","journal-title":"PLoS\u00a0One"},{"key":"98659_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1099\/jmm.0.000354","volume":"65","author":"TK Nyazika","year":"2016","unstructured":"Nyazika, T. K. et al. Cryptococcus neoformans population diversity and clinical outcomes of HIV-associated cryptococcal meningitis patients in Zimbabwe. J. Med. Microbiol. 65, 1281\u20131288 (2016).","journal-title":"J. Med. Microbiol."},{"key":"98659_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cyto.2015.07.025","volume":"76","author":"N Whibley","year":"2015","unstructured":"Whibley, N. & Gaffen, S. L. Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species. Cytokine 76, 42\u201352 (2015).","journal-title":"Cytokine"},{"key":"98659_CR8","first-page":"2","volume":"6","author":"SB Salazar","year":"2020","unstructured":"Salazar, S. B. et al. An overview on conventional and non-conventional therapeutic approaches for the treatment of candidiasis and underlying resistance mechanisms in clinical strains. J. Fungi (Basel) 6, 2 (2020).","journal-title":"J. Fungi (Basel)"},{"key":"98659_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/myc.13054","volume":"63","author":"DR Giacobbe","year":"2020","unstructured":"Giacobbe, D. R. et al. Changes in the relative prevalence of candidaemia due to non-albicans Candida species in adult in-patients: A systematic review, meta-analysis and meta-regression. Mycoses 63, 334\u2013342 (2020).","journal-title":"Mycoses"},{"key":"98659_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/microorganisms8020154","volume":"8","author":"S Costa-de-Oliveira","year":"2020","unstructured":"Costa-de-Oliveira, S. & Rodrigues, A. G. Candida albicans antifungal resistance and tolerance in bloodstream infections: The triad yeast-host-antifungal. Microorganisms 8, 2 (2020).","journal-title":"Microorganisms"},{"key":"98659_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.micpath.2018.02.028","volume":"117","author":"M Dadar","year":"2018","unstructured":"Dadar, M. et al. Candida albicans\u2014biology, molecular characterization, pathogenicity, and advances in diagnosis and control\u2014an update. Microb. Pathog. 117, 128\u2013138 (2018).","journal-title":"Microb. Pathog."},{"key":"98659_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","volume":"53","author":"K Satoh","year":"2009","unstructured":"Satoh, K. et al. Candida auris sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 53, 41\u201344 (2009).","journal-title":"Microbiol. Immunol."},{"key":"98659_CR13","first-page":"2","volume":"5","author":"DZP Friedman","year":"2019","unstructured":"Friedman, D. Z. P. & Schwartz, I. S. Emerging fungal infections: New patients, new patterns, and new pathogens. J. Fungi (Basel) 5, 2 (2019).","journal-title":"J. Fungi (Basel)"},{"key":"98659_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40560-018-0342-4","volume":"6","author":"A Cortegiani","year":"2018","unstructured":"Cortegiani, A. et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J. Intensive Care 6, 69 (2018).","journal-title":"J. Intensive Care"},{"key":"98659_CR15","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3389\/fmicb.2018.03081","volume":"9","author":"L Rossato","year":"2018","unstructured":"Rossato, L. & Colombo, A. L. Candida auris: What have we learned about its mechanisms of pathogenicity?. Front. Microbiol. 9, 3081 (2018).","journal-title":"Front. Microbiol."},{"key":"98659_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhin.2019.06.006","volume":"103","author":"B Short","year":"2019","unstructured":"Short, B. et al. Candida auris exhibits resilient biofilm characteristics in vitro: Implications for environmental persistence. J. Hosp. Infect. 103, 92\u201396 (2019).","journal-title":"J. Hosp. Infect."},{"key":"98659_CR17","first-page":"2","volume":"6","author":"TJ Gintjee","year":"2020","unstructured":"Gintjee, T. J., Donnelley, M. A. & Thompson, G. R. Aspiring antifungals: Review of current antifungal pipeline developments. J. Fungi (Basel) 6, 2 (2020).","journal-title":"J. Fungi (Basel)"},{"key":"98659_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12010029","volume":"12","author":"C Faustino","year":"2020","unstructured":"Faustino, C. & Pinheiro, L. Lipid systems for the delivery of amphotericin b in antifungal therapy. Pharmaceutics 12, 1 (2020).","journal-title":"Pharmaceutics"},{"key":"98659_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fphar.2019.00080","volume":"10","author":"T Di Mambro","year":"2019","unstructured":"Di Mambro, T., Guerriero, I., Aurisicchio, L., Magnani, M. & Marra, E. The Yin and Yang of current antifungal therapeutic strategies: How can we harness our natural defenses?. Front. Pharmacol. 10, 80 (2019).","journal-title":"Front. Pharmacol."},{"key":"98659_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd.2017.46","volume":"16","author":"JR Perfect","year":"2017","unstructured":"Perfect, J. R. The antifungal pipeline: A reality check. Nat. Rev. Drug Discov. 16, 603\u2013616 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"98659_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41579-019-0322-2","volume":"18","author":"J Berman","year":"2020","unstructured":"Berman, J. & Krysan, D. J. Drug resistance and tolerance in fungi. Nat. Rev. Microbiol. 18, 319\u2013331 (2020).","journal-title":"Nat. Rev. Microbiol."},{"key":"98659_CR22","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1128\/AAC.47.7.2208-2216.2003","volume":"47","author":"RC Matthews","year":"2003","unstructured":"Matthews, R. C. et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47, 2208\u20132216 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"98659_CR23","doi-asserted-by":"publisher","first-page":"403121","DOI":"10.1155\/2013\/403121","volume":"2013","author":"F Bugli","year":"2013","unstructured":"Bugli, F. et al. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin. Dev. Immunol. 2013, 403121 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"98659_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20050749","volume":"202","author":"A Torosantucci","year":"2005","unstructured":"Torosantucci, A. et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597\u2013606 (2005).","journal-title":"J. Exp. Med."},{"key":"98659_CR25","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1128\/IAI.00278-07","volume":"75","author":"A Rachini","year":"2007","unstructured":"Rachini, A. et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75, 5085\u20135094 (2007).","journal-title":"Infect. Immun."},{"key":"98659_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0145-305X(02)00039-3","volume":"27","author":"M-P Lefranc","year":"2003","unstructured":"Lefranc, M.-P. et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27, 55\u201377 (2003).","journal-title":"Dev. Comp. Immunol."},{"key":"98659_CR27","doi-asserted-by":"publisher","first-page":"14820","DOI":"10.1038\/s41598-018-32986-y","volume":"8","author":"A Clavero-\u00c1lvarez","year":"2018","unstructured":"Clavero-\u00c1lvarez, A., Di Mambro, T., Perez-Gaviro, S., Magnani, M. & Bruscolini, P. Humanization of antibodies using a statistical inference approach. Sci. Rep. 8, 14820 (2018).","journal-title":"Sci. Rep."},{"key":"98659_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jmb.2014.09.026","volume":"427","author":"P Sormanni","year":"2015","unstructured":"Sormanni, P., Aprile, F. A. & Vendruscolo, M. The CamSol method of rational design of protein mutants with enhanced solubility. J. Mol. Biol. 427, 478\u2013490 (2015).","journal-title":"J. Mol. Biol."},{"key":"98659_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15744\/2575-5498.2.101","volume":"2","author":"N Mf","year":"2017","unstructured":"Mf, N. et al. Quantitative analysis of candida cell wall components by flow cytometry with triple-fluorescence staining. J. Microbiol. Mod. Tech. 2, 1 (2017).","journal-title":"J. Microbiol. Mod. Tech."},{"key":"98659_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tcsw.2018.09.001","volume":"3","author":"KK Lee","year":"2018","unstructured":"Lee, K. K. et al. Yeast species-specific, differential inhibition of \u03b2-1,3-glucan synthesis by poacic acid and caspofungin. Cell Surf. 3, 12\u201325 (2018).","journal-title":"Cell Surf."},{"key":"98659_CR31","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.4049\/jimmunol.1402376","volume":"194","author":"MJ Davis","year":"2015","unstructured":"Davis, M. J. et al. Cryptococcus neoformans-induced macrophage lysosome damage crucially contributes to fungal virulence. J. Immunol. 194, 2219\u20132231 (2015).","journal-title":"J. Immunol."},{"key":"98659_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1039\/C5MB00599J","volume":"12","author":"D Chen","year":"2016","unstructured":"Chen, D., Zhang, H., Lu, P., Liu, X. & Cao, H. Synergy evaluation by a pathway-pathway interaction network: A new way to predict drug combination. Mol. Biosyst. 12, 614\u2013623 (2016).","journal-title":"Mol. Biosyst."},{"key":"98659_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drup.2009.03.001","volume":"12","author":"P Dent","year":"2009","unstructured":"Dent, P., Curiel, D. T., Fisher, P. B. & Grant, S. Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. Drug Resist. Update 12, 65\u201373 (2009).","journal-title":"Drug Resist. Update"},{"key":"98659_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1128\/CMR.17.2.268-280.2004","volume":"17","author":"MA Pfaller","year":"2004","unstructured":"Pfaller, M. A., Sheehan, D. J. & Rex, J. H. Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17, 268\u2013280 (2004).","journal-title":"Clin. Microbiol. Rev."},{"key":"98659_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11030-015-9625-z","volume":"20","author":"CL Gaughan","year":"2016","unstructured":"Gaughan, C. L. The present state of the art in expression, production and characterization of monoclonal antibodies. Mol. Divers 20, 255\u2013270 (2016).","journal-title":"Mol. Divers"},{"key":"98659_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/19420862.2016.1269580","volume":"9","author":"JM Reichert","year":"2017","unstructured":"Reichert, J. M. Antibodies to watch in 2017. MAbs 9, 167\u2013181 (2017).","journal-title":"MAbs"},{"key":"98659_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter, P. J. & Lazar, G. A. Next generation antibody drugs: Pursuit of the \u2018high-hanging fruit\u2019. Nat. Rev. Drug Discov. 17, 197\u2013223 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"98659_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","volume":"10","author":"H Kaplon","year":"2018","unstructured":"Kaplon, H. & Reichert, J. M. Antibodies to watch in 2018. MAbs 10, 183\u2013203 (2018).","journal-title":"MAbs"},{"key":"98659_CR39","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020).","journal-title":"Nat. Commun."},{"key":"98659_CR40","doi-asserted-by":"publisher","first-page":"e5392","DOI":"10.1371\/journal.pone.0005392","volume":"4","author":"A Torosantucci","year":"2009","unstructured":"Torosantucci, A. et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS\u00a0One 4, e5392 (2009).","journal-title":"PLoS\u00a0One"},{"key":"98659_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","volume":"26","author":"R Laniado-Labor\u00edn","year":"2009","unstructured":"Laniado-Labor\u00edn, R. & Cabrales-Vargas, M. N. Amphotericin B: Side effects and toxicity. Rev. Iberoam. Micol. 26, 223\u2013227 (2009).","journal-title":"Rev. Iberoam. Micol."},{"key":"98659_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1185\/030079903125001884","volume":"19","author":"DAJ Ullmann","year":"2003","unstructured":"Ullmann, D. A. J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 19, 263\u2013271 (2003).","journal-title":"Curr. Med. Res. Opin."},{"key":"98659_CR43","unstructured":"IgBlast tool. https:\/\/www.ncbi.nlm.nih.gov\/igblast\/."},{"key":"98659_CR44","unstructured":"SIB Swiss Institute of Bioinformatics|Expasy. https:\/\/www.expasy.org\/."},{"key":"98659_CR45","unstructured":"Home\u202f:: Chemistry of Health-software. http:\/\/www-cohsoftware.ch.cam.ac.uk\/\/index.php."},{"key":"98659_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1128\/AAC.00844-08","volume":"53","author":"A Kitamura","year":"2009","unstructured":"Kitamura, A., Someya, K., Hata, M., Nakajima, R. & Takemura, M. Discovery of a small-molecule inhibitor of \u03b2-1,6-glucan synthesis. Antimicrob. Agents Chemother. 53, 670\u2013677 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"98659_CR47","doi-asserted-by":"publisher","first-page":"e1007460","DOI":"10.1371\/journal.ppat.1007460","volume":"15","author":"S Singh","year":"2019","unstructured":"Singh, S. et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathog 15, e1007460 (2019).","journal-title":"PLoS Pathog"},{"key":"98659_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt0297-155","volume":"15","author":"W Magliani","year":"1997","unstructured":"Magliani, W. et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15, 155\u2013158 (1997).","journal-title":"Nat. Biotechnol."},{"key":"98659_CR49","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1038\/s41598-019-41513-6","volume":"9","author":"S Bhattacharya","year":"2019","unstructured":"Bhattacharya, S., Holowka, T., Orner, E. P. & Fries, B. C. Gene duplication associated with increased fluconazole tolerance in Candida auris cells of advanced generational age. Sci. Rep. 9, 5052 (2019).","journal-title":"Sci. Rep."},{"key":"98659_CR50","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/s41467-018-07738-1","volume":"9","author":"FM Rudkin","year":"2018","unstructured":"Rudkin, F. M. et al. Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat. Commun. 9, 5288 (2018).","journal-title":"Nat. Commun."},{"key":"98659_CR51","unstructured":"Arendrup, M. C. et al. EUCAST DEFINITIVE DOCUMENT E.DEF 7.3.2. 21 (2020)."},{"key":"98659_CR52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2217\/fmb.14.17","volume":"9","author":"B Canonico","year":"2014","unstructured":"Canonico, B. et al. Honey flavonoids inhibit Candida albicans morphogenesis by affecting DNA behavior and mitochondrial function. Future Microbiol. 9, 445\u2013456 (2014).","journal-title":"Future Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98659-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T23:03:25Z","timestamp":1675724605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98659-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98659-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.D.M. is employees at Diatheva s.r.l., E.M. and G.R. are employees at Takis s.r.l., M.M. holds shares in Diatheva s.r.l. Both companies have interest in developing antifungal agents. All the other authors do not have any conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19500"}}